Comparative Pharmacology
Head-to-head clinical analysis: PROCAINAMIDE HCL versus QUALAQUIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROCAINAMIDE HCL versus QUALAQUIN.
PROCAINAMIDE HCL vs QUALAQUIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Class Ia antiarrhythmic agent; blocks sodium channels, decreases phase 0 slope of action potential, prolongs refractory period, and increases action potential duration.
Quinine is a cinchona alkaloid that acts as a blood schizonticide against Plasmodium species. It inhibits heme polymerase in the parasite, leading to accumulation of toxic heme and parasite death. It also has weak gametocytocidal activity against P. vivax and P. malariae.
For life-threatening ventricular arrhythmias, IV: Loading dose: 100 mg administered at a rate of 25-50 mg/min, may repeat every 5 minutes until arrhythmia suppressed or up to a total of 500-1000 mg. Maintenance: IV infusion 1-4 mg/min. Oral: 250-500 mg every 3-6 hours; maximum 4 g/day.
325-650 mg orally every 6 hours as needed for pain; maximum 2.6 g/day.
None Documented
None Documented
Terminal elimination half-life: 2.5-4.7 hours (3 hours typical) in normal renal function; prolonged to 11-20 hours in renal impairment; NAPA half-life 6-8 hours (prolonged in renal failure).
Terminal elimination half-life approximately 8 hours in healthy adults; prolonged in hepatic impairment (up to 12-18 hours) and severe malaria (up to 14-20 hours).
Primarily renal (50-60% unchanged via glomerular filtration and tubular secretion) with 10-30% as N-acetylprocainamide (NAPA) metabolite; minor biliary/fecal (<5%).
Renal (approximately 20% unchanged; remainder as metabolites); biliary/fecal (minor).
Category A/B
Category C
Antiarrhythmic (Class Ia)
Antiarrhythmic (Class Ia)